Definition
Indatraline is a synthetic psychoactive compound that functions as a non‑selective reuptake inhibitor of the monoamine transporters for serotonin (5‑HT), dopamine (DA), and norepinephrine (NE). It is classified pharmacologically as a triple reuptake inhibitor (TRI) and has been investigated primarily in preclinical research on mood disorders and substance dependence.
Overview
Indatraline was first described in the scientific literature in the early 1990s by researchers seeking potent inhibitors of monoamine transporters. Unlike many clinical antidepressants that preferentially target one or two monoamine systems, indatraline exhibits comparable affinity for all three transporters, resulting in a broad increase of extracellular monoamine levels. The compound has been used experimentally to model the neurochemical effects of enhanced monoaminergic transmission and to assess the therapeutic potential of TRIs. Although it has demonstrated robust pharmacodynamic activity in animal models, indatraline has not progressed to market as a pharmaceutical drug, largely due to safety concerns and the availability of more selective agents.
Etymology / Origin
The name “indatraline” is derived from its chemical structure, which contains an indane core linked to a tricyclic scaffold. The suffix “‑aline” is commonly employed in the nomenclature of psychotropic agents (e.g., “amphetamine,” “sertraline”), indicating its classification within the broader family of central nervous system active compounds. The precise rationale for the prefix “inda‑” reflects the indane moiety present in the molecule.
Characteristics
- Chemical Structure: Indatraline is a substituted indane derivative with a phenylpropylamine side chain. Its IUPAC name is 1-(1,2‑dimethoxyphenyl)-2‑(2‑dimethoxyphenyl)propane‑1‑amine.
- Pharmacodynamics: It competitively inhibits the reuptake of 5‑HT, DA, and NE by binding to their respective transporters (SERT, DAT, NET) with nanomolar affinity. This inhibition raises synaptic concentrations of all three monoamines.
- Pharmacokinetics: In rodent studies, indatraline displays moderate oral bioavailability, a half‑life of several hours, and extensive hepatic metabolism primarily via oxidative demethylation. Human pharmacokinetic data are limited.
- Pharmacological Effects: Acute administration leads to increased locomotor activity, elevated mood‑related behaviors, and reduced depressive‑like phenotypes in animal assays. Chronic exposure has been shown to produce tolerance to some behavioral effects and to alter neuroadaptive pathways associated with monoamine signaling.
- Safety Profile: Preclinical toxicology indicates potential for cardiovascular effects (elevated blood pressure, tachycardia) and neurotoxicity at high doses. These risks, combined with the lack of selectivity, have limited its therapeutic development.
Related Topics
- Monoamine Transporters – Proteins that regulate synaptic levels of serotonin, dopamine, and norepinephrine (SERT, DAT, NET).
- Triple Reuptake Inhibitors (TRIs) – A class of compounds under investigation for major depressive disorder and other mood disorders.
- Indane‑Based Psychoactive Compounds – Chemical families that include indatraline, bupropion, and related molecules.
- Preclinical Models of Depression – Animal paradigms such as the forced swim test and sucrose preference test used to evaluate antidepressant‑like activity.
- Neurochemical Basis of Addiction – Research areas exploring how modulation of monoamine systems influences drug‑seeking behavior, wherein indatraline has been employed as a tool compound.